Validation and Test–Retest Repeatability Performance of Parametric Methods for [11C]UCB-J PET [PDF]
EJNMMI Research, 2022 [11C]UCB-J is a PET radioligand that binds to the presynaptic vesicle glycoprotein 2A. Therefore, [11C]UCB-J PET may serve as an in vivo marker of synaptic integrity.
Andor W J M Glaudemans +2 more
exaly +10 more sources
Improved Synthesis of SV2A Targeting Radiotracer [11C]UCB-J [PDF]
EJNMMI Radiopharmacy and Chemistry, 2019 Introduction [11C]UCB-J is a tracer developed for PET (positron emission tomography) that has high affinity towards synaptic vesicle glycoprotein 2A (SV2A), a protein believed to participate in the regulation of neurotransmitter release in neurons and ...
Jonas Eriksson +2 more
exaly +8 more sources
Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's disease [PDF]
NeuroImage, 2021 Purpose: 11C-UCB-J PET imaging, targeting synaptic vesicle glycoprotein 2A (SV2A), has been shown to be a useful indicator of synaptic density in Alzheimer's disease (AD).
Yihuan Lu +7 more
doaj +5 more sources
Potential of [11C]UCB-J as a PET tracer for islets of Langerhans [PDF]
Scientific Reports, 2021 Biomarkers for the measurement of islets of Langerhans could help elucidate the etiology of diabetes. Synaptic vesicle glycoprotein 2 A (SV2A) is a potential marker reported to be localized in the endocrine pancreas.
Emmi Puuvuori +5 more
doaj +7 more sources
Linking Resting-State Network Fluctuations With Systems of Coherent Synaptic Density: A Multimodal fMRI and 11C-UCB-J PET Study [PDF]
Frontiers in Human Neuroscience, 2023 Introduction: Resting-state network (RSN) connectivity is a widely used measure of the brain’s functional organization in health and disease; however, little is known regarding the underlying neurophysiology of RSNs.
Irina Esterlis +2 more
exaly +4 more sources
Human Biodistribution and Dosimetry of [11C]-UCB-J, a PET Radiotracer for Imaging Synaptic Density [PDF]
EJNMMI Physics, 2021 Rationale [11C]-UCB-J is an emerging tool for the noninvasive measurement of synaptic vesicle density in vivo. Here, we report human biodistribution and dosimetry estimates derived from sequential whole-body PET using two versions of the OLINDA dosimetry
Koen Van Laere +2 more
exaly +3 more sources
Feasibility of imaging synaptic density in the human spinal cord using [11C]UCB-J PET [PDF]
EJNMMI Physics, 2022 Purpose Neuronal damage and synapse loss in the spinal cord (SC) have been implicated in spinal cord injury (SCI) and neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS).
Samantha Rossano +7 more
doaj +4 more sources
Principal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s disease [PDF]
NeuroImage: Clinical, 2023 Background: Synaptic loss is considered an early pathological event and major structural correlate of cognitive impairment in Alzheimer’s disease (AD).
Ryan S. O'Dell +16 more
doaj +3 more sources
Automated GMP production and long-term experience in radiosynthesis of the SV2A tracer [11C]UCB-J [PDF]
EJNMMI Radiopharmacy and ChemistryBackground Positron emission tomography (PET) is a non-invasive imaging technique that enables the quantification of specific biological and pharmacological processes in vivo.
Saara Wahlroos +5 more
doaj +5 more sources
Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A [PDF]
EJNMMI Research, 2022 Background Antiepileptic drugs, levetiracetam (LEV) and brivaracetam (BRV), bind to synaptic vesicle glycoprotein 2A (SV2A). In their anti-seizure activity, speed of brain entry may be an important factor.
Mika Naganawa +14 more
doaj +2 more sources